Build assays that existing platforms cannot support
Advanced assays are driving the next phase of diagnostics. Existing systems cannot scale to meet them. A new architecture enables capability, economics, reimbursement pathways, and market expansion to grow together.
The same platform supports Guanine-developed assays, including the 20-minute sepsis inflammation panel, and OEM-developed assays across advanced biomarker categories. This creates a business model built on shared infrastructure, recurring cartridges, software-defined upgrades, and expanding assay menus.
The fastest-growing segments of biological measurement are structurally underserved
Biological diagnostics is shifting from simple assays to advanced measurement problems that require sensitivity, multiplexing, time resolution, and practical deployment together.
These are not niche use cases. They define the growth of clinical diagnostics, precision medicine, pharma workflows, and distributed biological measurement.
| Application | Representative Use Cases | TAM | Growth Profile |
|---|---|---|---|
| Low-Abundance Protein Biomarkers | Oncology, neurology, inflammatory disease | $10B+ | High |
| Rare Cells & Low-Concentration Pathogens | Sepsis, bloodstream infections, circulating tumor cells | $8B+ | High |
| Genetic Targets & Resistance Markers | Infectious disease, AMR, oncology mutations | $15B+ | High |
| Multi-Analyte Measurement | Host + pathogen, multi-omic panels | $12B+ | Very High |
| Time-Dependent Biological Response | Phenotyping, drug response, cellular activity | $10B+ | Very High |
| Distributed Deployment | Point-of-care, field, industrial systems | $20B+ | Very High |
| Sector | Opportunity |
|---|---|
| Clinical Diagnostics / Mobile Readers | $30B+ |
| Precision Medicine / High-Throughput Nodes | $45B+ |
| Industrial / Distributed Systems | $35B+ |
| Combined Platform Opportunity | $100B+ |
Existing systems were built for simple assays, not advanced ones
Legacy platforms are mature, specialized, and constrained by their underlying physics and workflows.
PCR, ELISA, culture, flow cytometry, and sequencing each solve part of the problem. None converge into a single architecture because they are bound to different sample assumptions, analyte types, signal models, and cost structures.
PCR
High nucleic-acid sensitivity, but limited analyte class, no phenotype, and escalating multiplex complexity.
ELISA / Immunoassay
Useful for simple protein tests, but limited multiplexing and poor fit for low-level, multi-marker panels.
Culture / AST
Provides functional truth, but too late for clinical decision windows and too infrastructure-heavy for scale.
Flow / NGS / LC-MS
High-complexity systems with high capital cost, centralized workflows, and limited deployability.
Legacy systems add capability by adding hardware complexity. Guanine expands capability on a shared architecture.
Advanced assay requirements align with a single architecture
The Nano-Bio-Info Scaling Law enables more biological information to be extracted per sample, across more analyte classes, with lower system complexity.
As advanced assays grow, systems that cannot support them remain fragmented. Systems that can unify sensitivity, multiplexing, time resolution, and practical deployment become structurally advantaged.
$6K–$8K systems instead of $30K–$1M+ classes of existing high-capability instruments.
Synthetic amplification with ~10⁶ tags per analyte on magnetic particles.
mL-scale sample processing rather than µL-only constraints for advanced assays.
Time-series response within a cartridge rather than static endpoint-only measurement.
| Requirement | Guanine Capability |
|---|---|
| Low abundance | Signal amplification and enrichment |
| Rare targets | Large-volume sample processing and magnetic concentration |
| Multiplex | Encoded signal architecture and shared electrochemical core |
| Multi-analyte | Unified sensing architecture across analyte classes |
| Dynamic biology | Time-series measurement in cartridge |
| Deployment | Low-cost, optics-free systems with near-patient potential |
Start with the 20-minute sepsis inflammation assay and build through value
The first commercial pathway is not the full platform all at once. It begins with an assay that is clinically urgent, economically compelling, and aligned with regulatory and payer adoption.
The 20-minute sepsis inflammation assay creates a BDP-aligned entry point:
Clinical value
Earlier triage and treatment alignment in a high-cost, high-mortality condition.
Payer value
Better decisions at a fraction of the capital and per-test cost of high-complexity systems.
Platform value
Creates an installed base and reimbursement pathway for expanded genotype, phenotype, and OEM assay layers.
Reimbursement begins with better value in a high-need use case and expands as additional assays are added on the same architecture.
Replicating the system requires reproducing the full signal stack
The moat is not a single assay or a single instrument. It is an interdependent signal architecture protected across multiple layers.
The core primitive is a patent-granted synthetic nanomaterial. Every subsequent capability builds on that foundation.
| Layer | Protected Capability | Status |
|---|---|---|
| Quadruplex Tag | Synthetic nanomaterial primitive enabling dense, reversible signal generation | Patent Granted |
| Amplification | Signal amplification architecture using magnetic particles and dense tag loading | Patent Granted |
| CME + MDWC | Composite multiplex encoding and adaptive waveform control | Patent Pending |
| Time-Series | Dynamic measurement and response tracking within cartridge workflows | Patent Pending |
Competitors would need to reproduce the full signal architecture—not individual components—to replicate the platform.
One architecture. Multiple revenue and market layers.
The investment case is defined by leverage. One sensing architecture supports Guanine assays, OEM assays, multiple reader tiers, recurring cartridges, software-defined upgrades, and cross-market expansion.
Infrastructure Layer
Shared sensing core across analyte classes and deployment tiers.
Revenue Layer
Readers, cartridges, software features, OEM development, and licensing.
Expansion Layer
Clinical, precision medicine, pharma, industrial, and distributed systems.
The next generation of diagnostics will be defined by advanced assays
Systems that cannot support them will remain constrained. Systems that can unify them will expand across markets.
Guanine is built on a scaling law that aligns with the fastest-growing segments of biological measurement, a reimbursement entry path beginning with sepsis inflammation, and an architecture-level moat that becomes stronger as the platform expands.
This is not a single-assay company. It is a platform built for the growth of advanced biological measurement.